|
|
|
|
|
|
|
|
abstract/open access
Abstract
Objective: To examine the effect of age on postoperative 30-day morbidity and mortality after surgery for ovarian cancer.
Methods:
The American College of Surgeons National Surgical Quality Improvement
Program files were used to identify patients with ovarian cancer who
underwent surgery in 2005 to 2011. Women were divided into 4 age groups:
<60, 60 to 69, 70 to 79, and ≥80 years. Multivariable logistic
regression models were performed.
Results:
Of 2087 patients included, 47% were younger than 60 years, 28% were 60
to 69 years old, 18% were 70 to 79 years old, and 7% were 80 years or
older. Overall 30-day mortality and morbidity rates were 2% and 30%.
Elderly patients 80 years or older were more likely to die within 30
days compared with patients younger than 60 years, 60 to 69 years old,
and 70 to 79 years old (9.2% vs. 0.6% vs .2.8% vs 2.5%, P < 0.001). Elderly patient aged 80 years or older were more likely to develop pulmonary (9% vs 2% vs 5% vs 3%, P < 0.001) and septic (9% vs 3% vs 5% vs 4%, P
= 0.01) complications compared with patients younger than 60 years, 60
to 69 years old, and 70 to 79 years old, respectively. No difference in
the risk of renal (0.2% vs 1% vs 1% vs 1%, P = 0.20) complications and surgical reexploration (4% vs 4% vs 3% vs 5%, P
= 0.80) between the 4 age groups. In multivariable analyses after
adjusting for other confounders, age was a significant predictor of
30-day postoperative mortality and morbidity. Compared with younger
patients, octogenarians were 9-times more likely to die and 70% more
likely to develop complications within 30 days after surgery. Other
significant predictors of 30-day mortality were higher American Society
of Anesthesiologists class and hypoalbuminemia (serum albumin ≤ 3 g/dL),
whereas, surgical complexity, higher American Society of
Anesthesiologists class, longer operative time, and hypoalbuminemia were
other significant predictors of 30-day morbidity.
Conclusions: Elderly patients have a higher risk of
perioperative mortality and morbidity within 30 days. Therefore, those
patients should be counseled thoroughly about the risk of primary
debulking surgery vs neoadjuvant chemotherapy.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.